|
Morbus Hodgkin 52 Arzneien acon. acon-l. am-m. ars. ars-br. ars-i. bar-c. bar-i. bar-m. buni-o. cadm-i. calc. calc-ar. calc-f. calc-i.*** carbn-s. carc. cean. cist. con.** dros. ferr-i.*** ferr-pic. fl-ac. hecla. hep. hydr. iod. kali-bi. kali-i. kali-m. krypt. lach. lap-a. merc. merc-i-r. merc-k-i. nat-lac. nat-m. nat-s. nit-ac. phos. psor. ruta.* saroth. scroph-n.* sil. sulph. sul-i. syph. tub. vinc. keine Fälle=ein- >1-2 Fälle=zwei- >2 Fälle=Drei- >5 Fälle=Vier- >10 Fälle=FÜNF-wertig ()=BegleitTherapie *=palliativ **=TeilWirkung ***=1-Jahr ****5-Jahre-Nachbeobachtung Complete-Nachträge wichtig, bzw. verlässlich |
| ^ | acon | c1 |
| ^ | acon-l | c1, sne |
| ^ | am-m | lby5 |
| ^ | ars | c1 |
| ^ | ars-br | vh |
| ^ | ars-i | bro1 |
| ^ | bar-c | Morrison |
| ^ | bar-i | bro1 |
| ^ | bar-m | vh |
| ^ | buni-o | jl |
| ^ | cadm-i | lby5 |
| ^ | calc | sne |
| ^ | calc-ar | lby5 |
| ^ | calc-f | c1 |
| ^ | calc-i | pha*** lby5 |
| ^ | carbn-s | lby5 |
| ^ | carc | rmk1 |
| ^ | cean | bn |
| ^ | cist | tl1, sne |
| ^ | con | sne2/Schwarz**, rzh(***) |
| ^ | dros | Tyler, CR |
| ^ | ferr-i | pha*** lby5 |
| ^ | ferr-pic | bro1 |
| ^ | fl-ac | lby5 |
| ^ | hecla | sne |
| ^ | hep | lby5 |
| ^ | hydr | lby5 |
| ^ | iod | bro1 |
| ^ | kali-bi | lby5 |
| ^ | kali-i | lby5 |
| ^ | kali-m | c1 |
| ^ | krypt | lby5 |
| ^ | lach | lby5 |
| ^ | lap-a | sne |
| ^ | merc | lby5 |
| ^ | merc-i-r | Lilienthal, CR |
| ^ | merc-k-i | gm, lby5 |
| ^ | nat-lac | Clarke, CR |
| ^ | nat-m | c1 |
| ^ | nat-s | Lilienthal, CR |
| ^ | nit-ac | Lilienthal, CR |
| ^ | phos | bro1 |
| ^ | psor | Lilienthal, CR |
| ^ | ruta | cpb1* |
| ^ | saroth | jl |
| ^ | scroph-n | cpb1* cpb, br1, sne |
| ^ | sil | lby5 |
| ^ | sulph | lby5 |
| ^ | sul-i | lby5 |
| ^ | syph | k, hr1 |
| ^ | tub | lby5 |
| ^ | vinc | Schmidt, CR |